Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
The New England Journal of Medicine|July 13, 2022
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's LymphomaStephen M Ansell, John Radford, Joseph M Connors, et al.
Blood Advances|January 25, 2024
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOPKurt S Bantilan, Alexandra N Smith, Matthew J Maurer, et al.
Blood|February 17, 2019
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphomaSven Borchmann, Erel Joffe, Craig H Moskowitz, et al.
Cancers|March 29, 2023
Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical SettingSerena Zheng, Kanika Gupta, Piyush Goyal, et al.
Haematologica|August 30, 2023
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluationZachary D Epstein-Peterson, Esther Drill, Umut Aypar, et al.
Blood|December 29, 2025
Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin LymphomaJeremy S Abramson, David J Straus, Nancy L Bartlett, et al.
American Journal of Hematology|July 12, 2021
Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohortsNeha Mehta-Shah, Matthew A Lunning, Alison J Moskowitz, et al.
Blood Advances|April 3, 2025
Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphomaNiloufer Khan, Parastoo B Dahi, Farhad Khimani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2022
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven ApproachLindsey E Roeker, Tatyana A Feldman, Jacob D Soumerai, et al.
Blood|January 17, 2020
Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 studyDavid J Straus, Monika Długosz-Danecka, Sergey Alekseev, et al.
Pageof 6